Regen BioPharma Inc (RGBP)

[soupoftheday]

Regen BioPharma starts NR2F6 T cell immunotherapy preclinical program

The program is to be carried out with Dr. Santosh Kesari, Director of Neuro-oncology at John Wayne Cancer Institute

If successful, the company added, these studies will serve as the basis for
a new cancer immunotherapeutic drug candidate, which would be useful as a monotherapy or adjuvant with other cancer immune therapies.

https://www.proactiveinvestors.co.uk/companies/news/119126/regen-biopharma-starts-nr2f6-t-cell-immunotherapy-preclinical-program-119126.html

Man On A Mission - Dr. Santosh Kesari